Tactile Systems Q2 revenue beats estimates
Overview
Tactile Systems Q2 revenue rises 7.8% yr/yr, beating analyst expectations, per LSEG data
Adjusted EBITDA for Q2 beats estimates, reaching $7.7 mln
Net income declines to $3.2 mln from $4.3 mln in Q2 2024
Outlook
Company expects 2025 revenue between $310 mln and $315 mln
Tactile Systems projects 2025 adjusted EBITDA of $33 mln to $35 mln
Company sees 2025 revenue growth of 6% to 8% year-over-year
Tactile Systems anticipates strategic investments to benefit results in 2026
Result Drivers
AIRWAY CLEARANCE SALES - 52% increase in sales driven by AffloVest placements among durable medical equipment (DME) partners
LYMPHEDEMA PRODUCTIVITY - 2% revenue growth attributed to increased field sales team headcount and productivity
LOWER COSTS - Gross profit rise due to reduced manufacturing and warranty costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $78.90 mln | $73.90 mln (5 Analysts) |
Q2 EPS | $0.14 | ||
Q2 Net Income | $3.20 mln | ||
Q2 Adjusted EBITDA | Beat | $7.70 mln | $7.39 mln (3 Analysts) |
Q2 Operating Income | $4.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Tactile Systems Technology Inc is $13.00, about 25.8% above its August 1 closing price of $9.65
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 20 three months ago
Press Release:
